Schistosomiasis Infections and Infestations Schistosomiasis [bilharziasis]
Conditions
Interventions
Study participants diagnosed with either S. mansoni, S. haematobium or both species concurrently will be treated with praziquantel (single 40 mg/kg oral dose, using crushed tablets)
Sponsors
Swiss Tropical and Public Health Institute (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, aged less than or equal to 72 months 2. Written informed consent by parents or legal guardian 3. Submission of two stool samples of sufficient size to prepare duplicate Kato-Katz thick smears from each sample at the baseline survey 4. Submission of two urine samples of sufficient amount for urine filtration method at the baseline survey 5. Provision of single fingerprick blood sample for malaria rapid diagnostic test and haemoglobin level assessment 6. Absence of major systemic illnesses, as assessed by medical personnel on the day of treatment
Exclusion criteria
Exclusion criteria: 1. Children aged more than 72 months 2. No written informed consent provided by by parents or legal guardian 3. Submission of less than two stool samples of sufficient size to prepare duplicate Kato-Katz smears from each sample at the baseline or follow-up survey 4. Submission of less than two urine samples of sufficient amount for urine filtration method at the baseline survey 5. No provision of fingerprick blood sample for malaria rapid diagnostic test and haemoglobin level assessment 6. Presence of any abnormal medical condition, as judged by the medical personnel on the day of treatment (e.g. clinical malaria) 7. Recent anthelminthic treatment (within 4 weeks) 8. Participation in other studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate and egg reduction rate of S. mansoni and S. haematobium, determined 3-4 weeks post-treatment by multiple stool sampling using the Kato-Katz method and multiple urine filtration tests | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency and severity of adverse events recorded within 24 hours after drug administration | — |
Countries
Cote d'Ivoire
Outcome results
None listed